Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.61 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.61 |
| ▸ | CCR3 | P51677 | 4/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23649319 | 0.83 | SLC6A2 (0.74) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL4853191 | 0.81 | SLC6A2 (0.71) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL24075739 | 0.80 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL4852114 | 0.78 | SLC6A2 (0.63) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL18568473 | 0.77 | SLC6A2 (0.72) | SLC6A2SLC6A3SLC6A4CCR3TMEM97 | |
| SCHEMBL10145310 | 0.76 | PRMT6 (1.00) | PRMT6CARM1CCR3TMEM97 | |
| SCHEMBL313395 | 0.76 | MEN1 (0.65) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL27016196 | 0.75 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| Hydrochloric Acid SCHEMBL9869544 | 0.75 | KCNH2 (0.65) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL24076758 | 0.74 | SLC6A2 (0.69) | SLC6A2SLC6A3SLC6A4CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057049-A | Carboxamide derivatives and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-02 | — | — | CN | claimed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| CN-116057049-A | Carboxamide derivatives and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-02 | — | — | CN | disclosed |
| EP-4159725-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | MAOA, DRD2, MAOB | SLC6A2 4/4885SLC6A3 13/4885SLC6A4 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.